Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NT5E | P21589 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.46 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.46 |
| ▸ | SLC29A1 | Q99808 | 5/20 | 0.44 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | PGK1 | P00558 | 1/20 | 0.42 |
| ▸ | PGK2 | P07205 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12702704 | 1.00 | NT5E (0.48) | NT5ELMNATP53CYP2C19ADORA3 | |
| SCHEMBL12702738 | 0.85 | ADORA2A (0.60) | NT5ELMNATP53ADORA3ADORA1 | |
| SCHEMBL1591903 | 0.85 | ADORA2A (0.60) | NT5ELMNATP53ADORA3ADORA1 | |
| SCHEMBL12702689 | 0.85 | ADORA2A (0.60) | NT5ELMNATP53ADORA3ADORA1 | |
| SCHEMBL1591804 | 0.85 | ADORA2A (0.60) | NT5ELMNATP53ADORA3ADORA1 | |
| SCHEMBL12702703 | 0.85 | ADORA2A (0.60) | NT5ELMNATP53ADORA3ADORA1 | |
| SCHEMBL12702733 | 0.85 | NT5E (0.48) | NT5ELMNATP53CYP2C19ADORA3 | |
| SCHEMBL12702741 | 0.85 | ADORA2A (0.60) | NT5ELMNATP53ADORA3ADORA1 | |
| SCHEMBL25354403 | 0.78 | PI4KA (0.66) | NT5ELMNATP53CYP2C19ADORA3 | |
| SCHEMBL7100664 | 0.77 | LMNA (0.78) | NT5ELMNATP53CYP2C19ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8846636-B2 | Nucleoside analogues with quaternary carbon stereogenic centers and methods of use | LCB PHARMA INC. (CA) | 2014-09-30 | — | — | US | disclosed |
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | INSTITUT DE RECHERCHES CLINIQUES DE MONTREAL (CA) | 2011-04-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110092451-A1 | NUCLEOTIDE ANALOGUES WITH QUATERNARY CARBON STEREOGENIC CENTERS AND METHODS OF USE | NUDT1, NT5C3B, NTPCR | NT5E 10/4885LMNA 1770/4885TP53 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.